Lung Cancer
A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)
- Details
ClinicalTrials.gov ID:
NCT04222972
Diagnosis Type:
NA
USOR Number:
- Address
18707 Hardy Oaks Blvd.
Suite 320
San Antonio, TX 78258
P: (210) 545-6972